<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02533973</url>
  </required_header>
  <id_info>
    <org_study_id>LP0076-1079</org_study_id>
    <nct_id>NCT02533973</nct_id>
  </id_info>
  <brief_title>Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 4 trial comparing the safety and efficacy of treatment with Xamiol® gel (calcipotriol
      50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) once daily (as required) with
      Daivonex® scalp solution (calcipotriol 50 mcg/g) twice daily (as required) in Chinese
      subjects with scalp psoriasis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 6, 2018</completion_date>
  <primary_completion_date type="Actual">March 6, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>safety of Xamiol® gel (adverse events)</measure>
    <time_frame>28 Weeks</time_frame>
    <description>To establish the safety of Xamiol® gel over a long period for up to 28 weeks of treatment in Chinese subjects. Incidence of adverse drug reactions of any type and Incidence of adverse events of concern associated with long-term corticosteroid use on the scalp.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Xamiol® gel ( percentage of visits in which subjects had &quot;Treatment success&quot; according to Investigator's Global Assessment)</measure>
    <time_frame>28 Weeks</time_frame>
    <description>To establish the efficacy of Xamiol® gel over a long period for up to 28 weeks of treatment in Chinese subjects. The percentage of visits in which subjects had &quot;Treatment success&quot; according to Investigator's Global Assessment of disease severity during the treatment. The percentage of visits in which subjects had &quot;Treatment success&quot; according to subject's global assessment of disease severity during the treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">951</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Xamiol® gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>calcipotriol 50mcg/g plus betamethasone 0.5 mg/g (as diproprionate) once daily as required, for up to 28 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>. Daivonex® scalp solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>calcipotriol 50mcg/g twice daily as required, for up to 28 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xamiol® gel</intervention_name>
    <arm_group_label>Xamiol® gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daivonex® scalp solution</intervention_name>
    <arm_group_label>. Daivonex® scalp solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed and dated informed consent has been obtained.

          2. Subjects of either gender 18 years of age or above.

          3. At visit 1, a clinical diagnosis of scalp psoriasis which is:

               -  of an investigator's assessment of clinical signs of the scalp of at least ≥ 2 in
                  one of the clinical signs, redness, thickness, and scaliness, and at least 1 in
                  each of the other two clinical signs, and total score ≥ 4

               -  of an extent of 10% or more of the total scalp area

               -  of at least mild severity according the investigator's global assessment

          4. Clinical signs of psoriasis vulgaris on trunk and/or limbs, or subject earlier
             diagnosed with psoriasis vulgaris on trunk and/or limbs.

          5. Female of childbearing potential using a reliable method of contraception for at least
             1 month before the trial start and during the course of the trial (e.g., oral
             contraceptive pill, intrauterine device, contraceptive patches, implantable
             contraception, condoms) or females of non-childbearing potential (i.e. postmenopausal
             (absence of menstrual bleeding for 2 years), hysterectomy, bilateral ovariectomy, or
             tubal section/ligation).

        Exclusion Criteria:

          1. Current diagnosis of guttate, erythrodermic, exfoliative, or pustular psoriasis.

          2. Subjects with any of the following conditions present on the scalp area: viral
             lesions, fungal and bacterial skin infections, parasitic infections, skin
             manifestations in relation to syphilis or tuberculosis, rosacea, acne vulgaris, acne
             rosacea, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis,
             ulcers, and wounds.

          3. Systemic treatment with biological therapies, whether marketed or not, with a possible
             effect on psoriasis vulgaris within the following time periods prior to randomisation
             and during the trial:

               -  etanercept (Yisaipu) - within 4 weeks prior to randomisation

               -  infliximab (Remicade) - within 2 months prior to randomisation

               -  other products: within 4 weeks/5 half-lives (whichever is longer) prior to
                  randomisation

          4. Systemic treatment with all other therapies with a possible effect on psoriasis
             vulgaris (e.g., corticosteroids, retinoids, methotrexate, ciclosporin and other
             immunosuppressant's, TCM [(traditional Chinese Medicine)]) within 4 weeks prior to
             randomisation or during the trial.

          5. PUVA therapy within 4 weeks prior to randomisation or during the trial.

          6. UVB therapy within 2 weeks prior to randomisation or during the trial.

          7. Therapies within 2 weeks prior to randomisation and during the trial:

               -  Topical treatment of body psoriasis with very potent (WHO group IV)
                  corticosteroids

               -  Topical treatment of face psoriasis with potent or very potent (WHO group III and
                  IV) corticosteroids

               -  Any topical treatment of the scalp (except for non-steroid medicated shampoos and
                  emollients)

          8. Known or suspected renal insufficiency or hepatic disorders or severe heart disease.

          9. Clinical signs or symptoms of Cushing's disease or Addison's disease.

         10. Known or suspected hypersensitivity to component(s) of IMPs

         11. Current participation in any other interventional clinical trial

         12. Subjects who have received treatment with any non-marketed drug substance (i.e. an
             agent which has not yet been made available for clinical use following registration)
             within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.

         13. Previously participated in a clinical trial within 4 weeks prior to randomisation.

         14. In the opinion of the (sub) investigator, the subject is unlikely to comply with the
             clinical trial protocol (e.g. due to alcoholism, drug addiction or psychotic state).

         15. Females who are pregnant, or of child-bearing potential and wish to become pregnant
             during the trial, or who are breast-feeding.

         16. Females of child-bearing potential with a positive urine pregnancy test at visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Zheng, MD, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Affiliated hospital Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

